
Nipocalimab shows sustained reduction in lupus disease activity in Phase 2 study, advancing to Phase 3 trials.
Johnson & Johnson's investigational drug nipocalimab significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) during a Phase 2 study, with effects sustained through 52 weeks. The drug targets pathoge...



